Nutrition and Dietetic Department, Flinders University of South Australia, Bedford Park 5042, South Australia, Australia.
World J Gastroenterol. 2012 Nov 28;18(44):6461-7; discussion p.6466. doi: 10.3748/wjg.v18.i44.6461.
To examine factors influencing percutaneous endoscopic gastrostomy (PEG) uptake and outcomes in motor neuron disease (MND) in a tertiary care centre.
Case notes from all patients with a confirmed diagnosis of MND who had attended the clinic at the Repatriation General Hospital between January 2007 and January 2011 and who had since died, were audited. Data were extracted for demographics (age and gender), disease characteristics (date of onset, bulbar or peripheral predominance, complications), date and nature of discussion of gastrostomy insertion, nutritional status [weight measurements, body mass index (BMI)], date of gastrostomy insertion and subsequent progress (duration of survival) and quality of life (QoL) [Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)]. In addition, the type of clinician initiating the discussion regarding gastrostomy was recorded as Nutritional Support Team (involved in providing nutrition input viz Gastroenterologist, Speech Pathologist, Dietitian) and other (involved in non-nutritional aspects of patient care). Factors affecting placement and outcomes including length of survival, change in weight and QoL were determined.
Case records were available for all 86 patients (49 men, mean age at diagnosis 66.4 years). Thirty-eight patients had bulbar symptoms and 48 had peripheral disease as their presenting feature. Sixty-six patients reported dysphagia. Thirty-one patients had undergone gastrostomy insertion. The major indications for PEG placement were dysphagia and weight loss. Nine patients required immediate full feeding, whereas 17 patients initially used the gastrostomy to supplement oral intake, 4 for medication administration and 1 for hydration. Initially the PEG regime met 73% ± 31% of the estimated total energy requirements, increasing to 87% ± 32% prior to death. There was stabilization of weight in patients undergoing gastrostomy [BMI at 3 mo (22.6 ± 2.2 kg/m(2)) and 6 mo (22.5 ± 2.0 kg/m(2)) after PEG placement compared to weight at the time of the procedure (22.5 ± 3.0 kg/m(2))]. However, weight loss recurred in the terminal stages of the illness. There was a strong trend for longer survival from diagnosis among MND in PEG recipients with limb onset presentation compared to similar patients who did not undergo the procedure (P = 0.063). Initial discussions regarding PEG insertion occurred earlier after diagnosis when seen by nutrition support team (NST) clinicians compared to other clinicians. (5.4 ± 7.0 mo vs 11.9 ± 13.4 mo, P = 0.028). There was a significant increase in PEG uptake (56% vs 24%, P = 0.011) if PEG discussions were initiated by the NST staff compared to other clinicians. There was no change in the ALSFRS-R score in patients who underwent PEG (pre 34.1 ± 8.6 vs post 34.8 ± 7.4), although in non-PEG recipients there was a non-significant fall in this score (33.7 ± 7.9 vs 31.6 ± 8.8). Four patients died within one month of the procedure, 4 developed bacterial site infection requiring antibiotics and 1 required endoscopic therapy for gastric bleeding. Less serious complications attributed to the procedure included persistent gastrostomy site discomfort, poor appetite, altered bowel function and bloating.
Initial discussion with NST clinicians increases PEG uptake in MND. Gastrostomy stabilizes patient weight but weight loss recurs with advancing disease.
在一家三级护理中心研究影响肌萎缩侧索硬化症(MND)患者经皮内镜下胃造口术(PEG)的使用和结局的因素。
对 2007 年 1 月至 2011 年 1 月期间在退伍军人总医院 MND 诊所就诊并已死亡的所有确诊 MND 患者的病历进行审核。提取数据包括人口统计学信息(年龄和性别)、疾病特征(发病日期、球部或周围为主、并发症)、PEG 插入讨论的日期和性质、营养状况[体重测量、体重指数(BMI)]、PEG 插入日期和后续进展(存活时间)和生活质量(QoL)[肌萎缩侧索硬化功能评定量表修订版(ALSFRS-R)]。此外,记录启动关于 PEG 讨论的临床医生类型为营养支持小组(参与提供营养输入,如胃肠病学家、言语病理学家、营养师)和其他(参与患者非营养方面的护理)。确定影响 PEG 放置和结局的因素,包括存活时间、体重变化和 QoL。
所有 86 例患者(49 名男性,诊断时平均年龄 66.4 岁)的病历均可用。38 例患者有球部症状,48 例患者有周围疾病作为首发症状。66 例患者报告有吞咽困难。31 例患者接受了 PEG 插入。PEG 放置的主要指征是吞咽困难和体重减轻。9 例患者需要立即全肠内喂养,而 17 例患者最初使用 PEG 补充口服摄入,4 例用于药物管理,1 例用于补液。最初,PEG 方案满足了 73%±31%的估计总能量需求,在死亡前增加到 87%±32%。接受 PEG 治疗的患者体重稳定[PEG 放置后 3 个月(22.6±2.2kg/m²)和 6 个月(22.5±2.0kg/m²)的 BMI 与手术时的体重(22.5±3.0kg/m²)相比]。然而,在疾病的终末期,体重再次下降。与未接受该手术的类似患者相比,肢体起病的 MND 患者在接受 PEG 治疗后从诊断开始的存活时间更长(P=0.063)。与其他临床医生相比,当由营养支持小组(NST)医生进行初始 PEG 插入讨论时,讨论时间更早(5.4±7.0 个月 vs 11.9±13.4 个月,P=0.028)。如果由 NST 工作人员启动 PEG 讨论,PEG 使用率显著增加(56% vs 24%,P=0.011)。接受 PEG 的患者的 ALSFRS-R 评分没有变化(术前 34.1±8.6 vs 术后 34.8±7.4),而在未接受 PEG 的患者中,该评分略有下降(33.7±7.9 vs 31.6±8.8)。4 例患者在手术后一个月内死亡,4 例患者发生细菌定植感染,需要使用抗生素治疗,1 例患者因胃出血需要内镜治疗。与该手术相关的较轻的并发症包括持续的胃造口部位不适、食欲减退、肠道功能改变和腹胀。
与 NST 临床医生进行初步讨论可增加 MND 患者对 PEG 的接受度。PEG 稳定患者的体重,但随着疾病的进展,体重会再次下降。